Hyaluronic Acid-based Products are Strictly Contraindicated in Scleroderma-related Skin Ulcers.


Journal

Wounds : a compendium of clinical research and practice
ISSN: 1943-2704
Titre abrégé: Wounds
Pays: United States
ID NLM: 9010276

Informations de publication

Date de publication:
Mar 2019
Historique:
entrez: 5 3 2019
pubmed: 5 3 2019
medline: 13 4 2019
Statut: ppublish

Résumé

Evidence of the role of hyaluronic acid (HA) in the tissue repair process is extensive. Hyaluronic acid produces a positive effect on skin ulcer healing, so many companies produce it in various topical applications. This retrospective, observational study examined the use of different HA-based products in patients with chronic skin ulcers of various etiologies (vascular, scleroderma, postoperative) to assess the indication, effectiveness, and possible adverse reactions. A retrospective case review was conducted on 79 patients presenting to the Department of Dermatology of the Spedali Civili (Brescia, Italy) with multiple chronic skin ulcers of the legs of various etiologies. The authors counted a total of 106 chronic wounds with granulating appearance but not responsive to common wound dressings; for this reason, these wounds were treated with a HA-based product. The efficacy of the treatment was evaluated by dividing the population into 2 groups: sclerodermic (41 ulcers) and nonsclerodermic (65 ulcers). Initial results confirmed HA-based products were effective for healing chronic skin wounds. However, when wounds are grouped by etiology, it was evident that patients with sclerodermic ulcers showed a rapid inflammatory response that led to a clinical deterioration and worsening of skin ulcers (92.7%). In contrast, patients with noninflammatory ulcers (vascular, postoperative) had the severe inflammatory event reduced to 1.5%, with a recovery of 98.5%. The negative effects of HA-based products on a patient with scleroderma could be explained by the fact that HA can produce a proinflammatory effect causing keratinocyte migration.

Identifiants

pubmed: 30830857

Substances chimiques

Hyaluronic Acid 9004-61-9

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

81-84

Auteurs

Giulio Gualdi (G)

Department of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.

Paola Monari (P)

Department of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.

Daniele Cammalleri (D)

Department of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.

Laura Pelizzari (L)

Department of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.

Piergiacomo Calzavara-Pinton (P)

Department of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH